Predictive value of neutrophil-to-lymphocyte ratio combined with carcinoembryonic antigen in postoperative adjuvant chemotherapy after gastric cancer surgery

Table 3 Cox subgroup analysis of postoperative neoadjuvant chemotherapy among neutrophil-to-lymphocyte ratio, carcinoembryonic antigen and neutrophil-to-lymphocyte ratio-carcinoembryonic antigen combined indicators

	Variable	Total	Event, n (%)	Follow up (time)	HR (95%CI)	P value
NLR_Low
	No chemotherapy	441	165 (37.4)	20024	1 (Ref)
	Chemotherapy	335	156 (46.6)	14443	0.64 (0.51-0.82)	0
NLR_High
	No chemotherapy	349	191 (54.7)	12575	1 (Ref)
	Chemotherapy	304	180 (59.2)	11268	0.71 (0.56-0.89)	0.004
CEA_Low
	No chemotherapy	252	149 (59.1)	8847	1(Ref)
	Chemotherapy	210	125 (59.5)	7660	0.64 (0.49-0.83)	0.001
CEA_High
	No chemotherapy	538	207 (38.5)	23752	1 (Ref)
	Chemotherapy	429	211 (49.2)	18051	0.72 (0.59-0.9)	0.003
NLR_CEA_ Low
	No chemotherapy	83	52 (62.7)	2832	1 (Ref)
	Chemotherapy	97	47 (48.5)	3872	0.41 (0.26-0.63)	0
NLR_CEA_ Middle
	No chemotherapy	387	154 (39.8)	16780	1 (Ref)
	Chemotherapy	318	167 (52.5)	13109	0.69 (0.54-0.87)	0.002
NLR_CEA_ High
	No chemotherapy	231	111 (48.1)	9089	1 (Ref)
	Chemotherapy	199	105 (52.8)	7844	0.73 (0.53-0.99)	0.042

NLR: Neutrophil-to-lymphocyte ratio; CEA: Carcinoembryonic antigen.